To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)

Inclusion Criteria: * Patients must be of non-childbearing potential and female patients must have a negative pregnancy test at the Screening Visit * Histologically and/or cytologically confirmed cancer with ECOG ≤2 * Life expectancy of ≥ 3 months * Assigned to receive the first cycle of a new multi-day chemotherapy regimen including the daily administration of cytotoxic agent(s) with the emetogenic potential of level 3-5 (Hesketh Classification) on 3-5 days Exclusion Criteria: * Hypersensitivity to adhesive plasters * Contraindications to 5-HT3 receptor antagonists * Clinically relevant abnormal laboratory values or hepatic, renal, infectious, neurological or psychiatric disorders or any other major systemic illness at the discretion of the Investigator * Any cause for nausea and vomiting other than CINV * Clinically relevant abnormal ECG parameters * Concomitant radiotherapy of total body, brain or upper abdomen within one week of study entry or planned during the study * A patient taking a medication to control the symptoms of a brain tumour, brain metastasis or seizure disorder